Trial intelligence / Profile preview

Empagliflozin vs sitagliptin added to metformin in type 2 diabetes

IRCT20160625028627N8Phase 2Completed

Sponsor
Kurdistan University of Medical Sciences
Start
Jul 2025
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin + metformin with Sitagliptin + metformin (2 arms). Started Jul 2025; status: completed.

02

Drugs

empagliflozinsitagliptinmetformin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on IRCT20160625028627N8.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20160625028627N8.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call